相关实验视频

Updated: Jun 23, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

miR-31-5p通过向Nfatc2ipp来抑制心肌缩

Lamei Zhao¹, Xiaotao Qian², Zhenxing Ren³

¹Department of Cardiology, 1st Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Journal of cellular and molecular medicine

|June 19, 2024

概括

一项新的研究显示,miR-31-5p通过准Nfatc2ip.p来抑制心脏缩. 这一发现发现了一种新的途径 (miR-31-5p/Nfatc2ip/β-Mhc),用于治疗心脏病的潜在治疗干预.

科学领域:

心脏病学心脏病学
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

心脏缩是对心肌压力的适应性反应,可以导致严重的心脏病和突然死亡.
在高缩期间观察到microRNA表达的变化,但它们的精确机制仍然不清楚.

研究的目的:

为了研究微RNAs在心脏缩中的作用.
阐明涉及miR-31-5p在心脏缩的发展中的特定分子途径.

主要方法:

在年轻的老鼠中确立腹腔大动脉缩 (AAC),以诱导心脏缩.
使用了体外和体内模型,包括新生小鼠心肌细胞.
进行了露西法酶试验和ChIP-qPCR来分析基因调节.

主要成果:

被AAC诱导的老鼠表现出心脏功能的下调,高调的多变性生物标志物和改变的microRNA配置文件,特别是显著降低了miR-31-5p.
发现miR-31-5p针对Nfatc2ip,抑制心肌缩.
证实Nfatc2ip对心脏缩至关重要,并直接增强了高缩基因β-Mhc的转录.

结论:

确定了一种新的miR-31-5p/Nfatc2ip/β-Mhc通路,与心脏缩有关.
miR-31-5p通过抑制Nfatc2ip及其下游效应,作为心脏缩抑制剂.
这一途径代表了管理心脏缩的潜在治疗标.

关键词:

Nfatc2ipip 的使用情况.miR-31-5p的时间.心肌缩过高是心肌缩的原因之一这就是β-Mhcc.

更多相关视频

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

相关概念视频

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...